Human Adenovirus Serotype 5 Is Sensitive to IgM-Independent Neutralization In Vitro and In Vivo.
Adenoviruses, Human
/ genetics
Animals
Antibodies, Viral
/ immunology
Cell Line
Complement Activation
Complement System Proteins
/ immunology
DNA-Binding Proteins
/ deficiency
Factor X
/ immunology
Humans
Immunoglobulin M
/ immunology
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Mutation
Neutralization Tests
Serogroup
Virion
/ immunology
complement components
human adenovirus 5
immune response
mouse IgM
virus neutralization
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
05 07 2019
05 07 2019
Historique:
received:
25
04
2019
revised:
23
06
2019
accepted:
03
07
2019
entrez:
10
7
2019
pubmed:
10
7
2019
medline:
1
8
2020
Statut:
epublish
Résumé
Human adenovirus 5 (HAdV-5) is used as a vector in gene therapy clinical trials, hence its interactions with the host immune system have been widely studied. Previous studies have demonstrated that HAdV-5 binds specifically to murine coagulation factor X (mFX), inhibiting IgM and complement-mediated neutralization. Here, we examined the physical binding of immune components to HAdV-5 by nanoparticle tracking analysis, neutralization assays, mass spectrometry analysis and in vivo experiments. We observed that purified mouse Immunoglobulin M (IgM) antibodies bound to HAdV-5 only in the presence of complement components. Active serum components were demonstrated to bind to HAdV-5 in the presence or absence of mFX, indicating that immune molecules and mFX might bind to different sites. Since binding of mFX to HAdV-5 blocks the neutralization cascade, these findings suggested that not all complement-binding sites may be involved in virion neutralization. Furthermore, the data obtained from serum neutralization experiments suggested that immune molecules other than IgM and IgG may trigger activation of the complement cascade in vitro. In vivo experiments were conducted in immunocompetent C57BL/6 or immuno-deficient
Identifiants
pubmed: 31284434
pii: v11070616
doi: 10.3390/v11070616
pmc: PMC6669743
pii:
doi:
Substances chimiques
Antibodies, Viral
0
DNA-Binding Proteins
0
Immunoglobulin M
0
Rag2 protein, mouse
0
Factor X
9001-29-0
Complement System Proteins
9007-36-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : British Heart Foundation
ID : CH/11/2/28733
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M011542/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/L027933/1
Pays : United Kingdom
Références
Hum Gene Ther. 1999 Apr 10;10(6):965-76
pubmed: 10223730
Hum Gene Ther. 2002 Jan 1;13(1):113-24
pubmed: 11779415
Hum Gene Ther. 2002 Jan 1;13(1):143-54
pubmed: 11779418
J Virol. 2005 Jun;79(12):7478-91
pubmed: 15919903
Cancer Gene Ther. 2006 Feb;13(2):169-81
pubmed: 16082381
J Clin Microbiol. 2005 Sep;43(9):4426-33
pubmed: 16145087
Blood. 2006 Oct 15;108(8):2554-61
pubmed: 16788098
Blood. 2009 Jul 30;114(5):965-71
pubmed: 19429866
Adv Immunol. 2009;104:115-49
pubmed: 20457117
Blood. 2010 Oct 14;116(15):2656-64
pubmed: 20610817
PLoS Pathog. 2010 Oct 07;6(10):e1001142
pubmed: 20949078
Methods Mol Med. 1999;30:271-83
pubmed: 21341032
Eur J Immunol. 1990 Dec;20(12):2555-61
pubmed: 2148521
Nat Med. 2013 Apr;19(4):452-7
pubmed: 23524342
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Expert Opin Drug Deliv. 2014 Nov;11(11):1795-813
pubmed: 25036189
PLoS Pathog. 2015 Feb 06;11(2):e1004673
pubmed: 25658827
Hum Gene Ther. 2015 May;26(5):312-9
pubmed: 25760682
Gene Ther. 2016 Jul;23(7):592-6
pubmed: 27014840
Oncotarget. 2017 Feb 28;8(9):15553-15562
pubmed: 28152519
J Virol. 2017 May 26;91(12):
pubmed: 28381574
PLoS One. 2018 Feb 5;13(2):e0192353
pubmed: 29401488
Cell Host Microbe. 2019 Apr 10;25(4):617-629.e7
pubmed: 30926239
J Immunol. 1998 May 15;160(10):4776-87
pubmed: 9590224
Biochemistry. 1998 Dec 15;37(50):17361-70
pubmed: 9860851